STANDARD BIOTOOLS INC

Carey Thomas D.’s recent insider purchase signals confidence in Standard BioTools’ future—RSUs and options could drive a rebound after a 27‑month decline.

CEO Michael Egholm’s zero‑cost RSU purchases show strong insider confidence in Standard BioTools, signaling a long‑term growth bet and a potential catalyst for investor interest.

Insider confidence drives Standard BioTools shares up—Casdin Eli buys 53k shares at $1.17 amid mixed exec sales, hinting at future growth in diagnostics and micro‑fluidics.

Insider buying signals confidence in Standard BioTools – executives’ RSU purchase after earnings shows long‑term commitment and may hint at future upside as R&D matures.